Angiogenesis inhibitors derived from thalidomide

被引：58
作者：
Noguchi, T [1 ]
Fujimoto, H [1 ]
Sano, H [1 ]
Miyajima, A [1 ]
Miyachi, H [1 ]
Hashimoto, Y [1 ]
机构：
[1] Univ Tokyo, Bunkyo Ku, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2005年 / 15卷 / 24期
基金：
日本学术振兴会;
关键词：
thalidomide; angiogenesis; HUVEC; phthalimide; structural development;
D O I：
10.1016/j.bmcl.2005.08.086
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
5-Hydroxy-2-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33: 10), which was obtained during our previous structural development studies on thalidomide, was revealed to possess potent anti-angiogenic activity in a human umbilical vein endothelial cell (HUVEC) assay. Thalidomide (1) and its metabolite, 5-hydroxythalidomide (5-HT: 2), which possesses a hydroxyl group at the position corresponding to that of 5HPP-33, as well as IMiDs (immunomodulatory derivatives of thalidomide: 3 and 5), also showed weak or moderate activity in the same assay. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码：5509 / 5513
页数：5
相关论文
共 27 条
  • [1] Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents
    Bartlett, JB
    Dredge, K
    Dalgleish, AG
    [J]. NATURE REVIEWS CANCER, 2004, 4 (04) : 314 - 322
  • [2] Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
    Bauer, KS
    Dixon, SC
    Figg, WD
    [J]. BIOCHEMICAL PHARMACOLOGY, 1998, 55 (11) : 1827 - 1834
  • [3] Thalidomide: Current and potential clinical applications
    Calabrese, L
    Fleischer, AB
    [J]. AMERICAN JOURNAL OF MEDICINE, 2000, 108 (06) : 487 - 495
  • [4] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS
    DAMATO, RJ
    LOUGHNAN, MS
    FLYNN, E
    FOLKMAN, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) : 4082 - 4085
  • [5] Thalidomide on the comeback trail
    Hales, BF
    [J]. NATURE MEDICINE, 1999, 5 (05) : 489 - 490
  • [6] Hashimoto Y, 1998, CURR MED CHEM, V5, P163
  • [7] Tubulin-polymerization inhibitors derived from thalidomide
    Inatsuki, S
    Noguchi, T
    Miyachi, H
    Oda, S
    Iguchi, T
    Kizaki, M
    Hashimoto, Y
    Kobayashi, H
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (02) : 321 - 325
  • [8] Anti-androgens with full antagonistic activity toward human prostate tumor LNCaP cells with mutated androgen receptor
    Ishioka, T
    Tanatani, A
    Nagasawa, K
    Hashimoto, Y
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (16) : 2655 - 2658
  • [9] Novel non-steroidal/non-anilide type androgen antagonists with an isoxazolone moiety
    Ishioka, T
    Kubo, A
    Koiso, Y
    Nagasawa, K
    Itai, A
    Hashimoto, Y
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (05) : 1555 - 1566
  • [10] KAKUTA H, 2001, RRD MED CHE, V1, P189
123